A Phase I, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults.

Trial Profile

A Phase I, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs V 212 (Primary)
  • Indications Herpes zoster
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 18 Nov 2009 Planned end date changed from 1 Feb 2010 to 1 Feb 2009 as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Planned number of patients changed from 160 to 288 as reported by ClinicalTrials.gov.
    • 14 Oct 2009 Planned number of patients changed from 288 to 160 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top